Frontlight ResearchEarly access
WithdrawnPhase 2
Efficacy of Traumatic Memory Modification Using Memory Reconsolidation and Propranolol Among Adolescents With PTSD
Key facts
- Who runs it
- Rennes University Hospital
- Where
- France10 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- Oct 2024
- Ended
- Jun 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Propranolol
- Placebo
- Record updated
- 8 September 2025
- Why it stopped
- The study could not begin within the period of validity of the authorizations. The project has been abandoned in its initially authorized form. The final study report will not be produced.
Who can take part
- Age
- 12 years to 18 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- - Adolescents aged 12 to 18 years
- Exposed to a single traumatic event or to events circumscribed in time, including sexual abuse in the absence of reminders in the environment
- Fluent in French
- Positive diagnosis of PTSD with the SCID-5
- Disorders evolving for at least three months
- Heart rate ≥ 55 bpm
- Systolic blood pressure ≥ 100 mmHg
- Written parental or legal guardian consent
- Written agreement by the adolescent
- Adolescents affiliated, via their parents, to the French social security body
Who cannot take part
- Currently treated with a drug that can interfere with propranolol and that can represent a danger according to medical advice if it's suspended more than 24 hours
- Currently treated with a bradycardic drug
- Concurrent psychotropic medication with the exception of cyamemazine (suspended 48 hours before session)
- Concurrent trauma-focused psychotherapy in progress or stopped less than 1 month ago
- Current use of "recreative" toxic drugs
- Concurrent participation to another interventional study
- - Medical condition contraindicating administration of propranolol (COPD, asthma, cardio-vascular insufficiency, heart failure as second- and third-degree atrioventricular blocks, Prinzmetal angor, pheochromocytoma, Raynaud disease, history of an anaphylactic reaction, sinus node disease, hypoglycemia, AV blocks)
- Known chronic renal or hepatic insufficiency
- Autism spectrum disorder
- Currently treated for Attention Deficit Hyperactivity Disorder
- Schizophrenia
- Mental retardation
- Acute severe suicidal ideation
- Traumatic brain injury (loss of consciousness > 10 minutes)
- Currently treated for substance or alcohol dependence
- Pregnancy or breast feeding
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this study is to demonstrate the effectiveness of propranolol in blocking reconsolidation by reducing PTSD symptoms in the short and long term in adolescents with PTSD for more than 3 months.
The 2 groups in the trial
- PropranololTreatment being tested
- PlaceboPlacebo, for comparison
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Efficacy of Traumatic Memory Modification Using a Memory Reconsolidation Procedure Under Propranolol Among Adolescents With Post-traumatic Stress Disorder
- Record updated
- 8 September 2025